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The 2014 Varsity Medical Ethics debate convened upon the motion: “This house believes that genetic information
should not be commoditised”. This annual debate between students from the Universities of Oxford and Cambridge,
now in its sixth year, provided the starting point for arguments on the subject. The present article brings together and
extends many of the arguments put forward during the debate. We explore the circumstances under which genetic
material should be considered patentable, the possible effects of this on the research and development of novel
therapeutics, and the need for clear guidelines within this rapidly developing field.
The Varsity Medical Debate was first held in 2008 with the aim of allowing students to engage in discussion about
ethics and policy within healthcare. Two Oxford medical students, Mahiben Maruthappu and Sanjay Budheo founded
the event. The event is held annually and it is hoped that this will allow future leaders to voice a perspective on the
arguments behind topics that will feature heavily in future healthcare and science policy. This year the Oxford University
Medical Society at the Oxford Union hosted the debateBackground
Over the past decade, research into the therapeutic ap-
plications of genetics has grown substantially [1]. The
cost of developing new therapies and pursuing new lines
of research requires that commercial research companies
have some way of recovering costs and making profit
from such vast research and development (R&D) ex-
penditure. Patents grant the owner rights to prevent
others from selling or benefitting from any product or
method that they have invented and these are usually
valid for 20 years [2]. In the United States, patents are
only granted to those inventions that are deemed novel,
non-obvious and that have a clear use (the “utility re-
quirement”) [3]. The granting of a patent requires that
the inventor divulge information about the creation of
that product, such that others are able to see how the in-
vention is made and how it works [4]. This is distinct
from trade secrets, where an inventor or a company
must keep the details of the invention to themselves —
trade secrets do not prevent independent invention by a
third party. UK Law does not allow for the patenting of* Correspondence: rajdattani@gmail.com
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ploitation would be contrary to existing law [4].
In the context of genetics, patents have been sought
for a wide range of different “inventions”, most of which
result from the isolation and cloning of specific se-
quences of nucleic acid bases [5]. The utility require-
ment for a patent to be granted necessitates that these
sequences have some function, whether in the form of
coding for particular genes, or having some correlation
with increased risk of some condition: they cannot sim-
ply be random sequences of bases that have been iso-
lated from cells. The standard for utility set by the
United States of America (USA) Patent and Trademark
Office is that “a person of ordinary skill in the art would
immediately appreciate why the invention is useful based
on the characteristics of the invention… and the utility is
specific, substantial and credible” [6]. In this article we
will discuss modern applications of patenting to genet-
ics, such as those for diagnostic tests or treatments uti-
lising genetic vectors. We argue that valid objections to
the patenting of genetic products stem must therefore
be made on these grounds of utility and novelty require-
ments, and whether the spirit of these requirements are
respected.article distributed under the terms of the Creative Commons Attribution License
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Taken in its widest sense a patent for a gene may be
granted for any sequence of bases. Synthetic poliovirus
genomes, constructed in vitro from scratch, have been
inserted into living organisms [7]; any genetic product
constructed in this way could, in theory, be patented.
Even if such a sequence of bases is specifically designed
(i.e not isolated from a living organism) it is not beyond
possibility that a random in vivo mutation could create
the same sequence. The issue of patenting parts of living
organisms must therefore be borne in mind for all cases
of genetic patenting. Objections to genetic patenting on
these grounds are based on the claim that nucleic acid
sequences are common to all living organisms, and,
given that such random mutations can occur, any such
patent claim cannot be truly novel.
It would be problematic for the enforcement of the pa-
tent if people were able to isolate, literally from them-
selves, a random sequence of nucleic acid bases and
then patent these. Yet in both the UK and Europe the
patenting of isolated naturally occurring sequences is
still largely permitted [8]. But does the simple isolation
of a gene or genetic sequence really merit a patent? We
argue that it does not; especially given that the sequence
of the human genome is already known and location of
the majority of genes have already been identified. Isola-
tion only requires use of simple pattern recognition and
long established molecular biology techniques – hardly a
demonstration of innovation worthy of a patent.
In keeping with the utility requirement for patentability,
most patents concerning genetic isolation are granted to
the processes that facilitate the quantification or genotyp-
ing of a gene for the purposes of investigating a specific
disease. The knowledge gained from genotype studies of
Apolipoprotein E (ApoE) variants in the population has
been patented for commercial exploitation in a wide var-
iety of conditions, ranging from the role of ApoE in deter-
mining the susceptibility to early-onset Alzheimer’s [9],
the likely effectiveness of cholinomimetic treatment in pa-
tients with Alzheimer’s [10], the predisposition to lipopro-
tein abnormalities and cardiovascular disease and the
predisposition to prostate cancer [11].
A further step in the process, once a gene has been
isolated and its role in a disease state quantified, is the
use of the gene as a genetic test or screening tool: an ap-
plication which could in theory be patented. The Myriad
patent of BRCA1 [12] and BRCA2 [13] is an example of
a patent granted for an isolated gene sequence. Certain
polymorphisms of the BRCA genes are known to in-
crease risk of breast and ovarian cancer and Myriad was
the first to successfully isolate and identify these genes.
The isolated gene sequence has then formed the basis for
a genetic test for the cancer risk increasing forms. How-
ever, a recent USA court case, Association for MolecularPathology v. Myriad Genetics [14], overturned the Myriad
patent and produced a precedent for disallowing the
patenting of simple isolated sequences. So while an iso-
lated sequence may have a utility as part of a genetic test,
there is a strong argument to say that identification of
such a sequence is no innovative and thus not worthy
of a patent.
There are, however, circumstances were the utilisation
of an existing human genetic sequence can, in our view,
fulfil the requirements set out above and therefore form
the basis of a patentable commodity. In the case of gen-
etic vectors, the same reasoning can be applied, recog-
nising that there is a significant innovative steps present
between the isolation of a nucleic acid sequence and the
packaging, delivery and efficacy of such sequence as a
therapeutic vector. For example creation of process that
delivers a gene via a viral vector requires novel work and
more time than simply isolating a gene. The difference
between gene therapies and simple gene isolation can be
considered due to the technical work involved in creat-
ing a new therapy and (perhaps more importantly) the
utility of said therapy. Unlike an isolated gene, a therapy
is truly novel and has a clear and obvious benefit.
Current practice and implications of genetic patenting
As mentioned previously, current EU patent law does
allow for the patenting of isolated nucleic acid sequences
[8]. We can therefore ask whether changing to disallow
such patents would actually provide any benefit. In the
UK non-compliance is very high and there is little evi-
dence that patent holders take action against those in
breach of patent [15]. On the other hand, when a patent
is upheld and defended, this has the potential to ser-
iously limit research. Unlike a vector based genetic ther-
apy, which is a ‘finished product’ with a clear use and
benefit, gene isolation is the beginning of the research
process. If a company successfully patents a specific
gene, it could, in theory, then limit all further research
into that sequence. While this may be appropriate in a
sequence where its role and potential therapeutic benefit
has been fully characterised, in other sequences this
could have serious consequences. For example, if the
TP53 gene sequence (which produces the tumour sup-
pressor protein, p53) had been patented and the patent
upheld, all research into p53 and its importance in can-
cer may have been stopped. A patent allows a company
to carry out all the research itself, and in a genetic se-
quence with many functions (like TP53) it seems very
unlikely that all possible functions could be charac-
terised by one laboratory or company. However if taken
in its current legal sense this is indeed the case: in
Madey vs Duke, a case concerning a patented laser, the
court ruled that any further research that was “not solely
for amusement, to satisfy idle curiosity or for strictly
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tent [16]. It might therefore be suggested that whilst
allowing patents on therapeutic vectors encourages re-
search and innovation by providing a commercial incen-
tive, allowing patents on isolated, naturally occurring
sequences is more likely to limit research. The fact that
it has not done this so far in the UK is because patents
have not been upheld, however there is nothing to pre-
vent a change of attitudes in line with the rapidly chan-
ging landscape. Why then are current attitudes averse to
pursuing infringements of patents legally? Firstly, it is
difficult to definitely prove consequential damages aris-
ing solely from research on a nucleic acid sequence
when there has been no commercialisation of a further
product. Secondly, in practice, commercial companies
often stand to gain commercially from a symbiotic rela-
tionship with academic researchers who investigate their
patented sequence: the researchers gain academic cre-
dence and output in the form of publications whist the
patent holder gains from knowledge produced at no
direct cost to themselves. From a public benefit view-
point, it is vastly preferable to have patents predominate
over the alternative: knowledge stored as a trade secret.
Patenting requires that the details of the “invention” are
made public. This allows for further research to be carried
out by a variety of scientists with different viewpoints, po-
tentially increasing the number of uses of any one nucleic
acid sequence as its roles are further characterised.
Conclusion
An environment needs to exist which allows for both in-
tellectual property rights to incentivise commercial en-
deavour whilst also being open to collaborative research
with the ultimate aim of promulgating new technology
for therapeutic benefit. We have argued here that the
cautious use of patenting can allow for the creation of
new genetic therapeutics, in terms of both convincing
the pharmaceutical industry of investing in R&D and
providing an open platform of research to the wider sci-
entific community. However, we argue that the current
stage at which patents are granted (i.e simply for isolat-
ing sequences) in genetics is too early: this is evidenced
both on the novelty and utility requirements applied to
patents in general, as well as the evidence from current
practice and the implications for public benefit.
About the debate
After a passionate display from both sides, the judges
awarded victory to the Oxford team this year. The key
area of contention throughout the debate was that of
creating an environment which fostered the growth of
innovative research in this rapidly developing scientific
field. Cambridge, in proposition, argued that well regu-
lated patenting would provide economic incentive topromote developments in the field, which would ultim-
ately provide meaningful therapeutic benefit to the
population at large. However, it was Oxford’s view that
the patenting of a gene would essentially commodify
naturally occurring genetic sequences and that this
posed a significant risk to society. Oxford’s main argu-
ments focussed on the fact that patenting naturally oc-
curring sequences did not necessarily require any novel
innovation. Oxford argued that, in fact, such patenting
might act as a limit on gene research by incentivising com-
panies to simply identify genes rather than gene products.
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